Industry Asks CMS Not To Tread On FDA's Medtech Safety Authority
This article was originally published in The Gray Sheet
Executive Summary
CMS should leave questions regarding medtech safety to FDA rather than re-examine them in coverage with evidence development studies, according to physicians and industry stakeholders.
You may also be interested in...
CMS Coverage-With-Evidence-Development Policy Could Face Revamp
CMS is taking comments through Jan. 6 on implementation of CED policies as part of national coverage determinations, how CED impacts Medicare beneficiaries and how new approaches might maximize benefits.
CMS Changes Gears On MRI Coverage In Pacemaker Patients
Under an April 25 proposal, pacemaker patients not enrolled in a clinical trial would be eligible for Medicare-reimbursed magnetic resonance imaging scans, under certain conditions, if their implant is FDA-approved for use in the MRI environment.
CMS Changes Gears On MRI Coverage In Pacemaker Patients
Under an April 25 proposal, pacemaker patients not enrolled in a clinical trial would be eligible for Medicare-reimbursed magnetic resonance imaging scans, under certain conditions, if their implant is FDA-approved for use in the MRI environment.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: